NCT01784900

Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab

Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab. A Randomized Phase II Trial.

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Treatment by association of complete surgical excision of the lesions and intraperitoneal immunotherapy using Catumaxomab for patients with gastric peritoneal carcinomatosis

Conditions

• Patients With Gastric Peritoneal Carcinomatosis

Interventions

Type	Name	Description
DRUG	Catumaxomab 100µg
DRUG	Catumaxomab 140µg

Timeline

• Start date: 2012-11-01
• Primary completion: 2016-01-01
• Completion: 2016-01-01
• First posted: 2013-02-06
• Last updated: 2017-01-26

Locations

1 site across 1 country: France